Revive Therapeutics Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Frank
- Full Time Employees
- 2
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- The Canadian Venture Building Toronto ON Canada M5C 1P1
- IPO Date
- Jul 12, 2013
- Website
- revivethera.com
- Similar Companies
- Business
- Revive Therapeutics Ltd. is a clinical-stage pharmaceutical company primarily engaged in the development and commercialization of therapeutics for rare and infectious diseases, as well as mental health disorders. The company’s core product portfolio includes psychedelic-based therapeutics and conventional pharmaceuticals, focusing on the development of treatments such as psilocybin for mental health conditions including depression and anxiety; Bucillamine as a potential treatment for COVID-19 and other infectious diseases; and other novel small molecule drugs. Revive Therapeutics’ key services encompass clinical trial management, drug development, and regulatory affairs focused on advancing its innovative drug pipeline. The company operates mainly in North America, with research and development activities headquartered in Toronto, Canada, where it was founded in 2015. Recent major company developments include strategic partnerships and collaborations to advance clinical trials of its psychedelic and pharmaceutical assets, expanded research into novel infectious disease treatments highlighted by recent clinical studies on Bucillamine, and the launch of new product development initiatives targeting both mental health and infectious disease markets. In the last 1-2 years, the company has made significant progress in regulatory approvals and trial milestones that underscore its strategic shift toward psychedelic-assisted medicine and rare disease therapeutics. Additionally, Revive Therapeutics has secured new funding rounds to accelerate its clinical pipeline and expand its operational capabilities. No recent name change or reorganization has been reported. Revive Therapeutics operates within the pharmaceutical and biotechnology industry, specifically within the segments of mental health, rare diseases, and infectious disease drug development. Its target markets include healthcare providers, pharmaceutical distributors, and research institutions primarily across Canada and the United States. The company’s emphasis on psychedelic medicine and innovative infectious disease therapeutics positions it at the forefront of contemporary pharmaceutical research and development with a growing focus on clinical-stage and near-market readiness of its product candidates. This comprehensive scope of products, strategic developments, and geographic focus defines Revive Therapeutics Ltd. as a specialized clinical-stage pharmaceutical entity dedicated to advancing novel therapies for significant unmet medical needs.
Company News
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Revive Therapeutics Announces Proposed Shares for Debt Settlement
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
Revive Therapeutics Reports Grant of Options
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Revive Therapeutics Announces Proposed Private Placement
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Revive Therapeutics Announces Extension of Proposed Private Placement
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Revive Therapeutics Advances with Next-Generation Bucillamine Development
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics Announces Proposed Shares for Debt Transaction